Company Description
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.
Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development.
GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Dr. W. Marc Hertz Ph.D. |
Contact Details
Address: 2223 Avenida De La Playa, Suite 208 La Jolla, California 92037 United States | |
| Phone | (619) 400-1171 |
| Website | gribio.com |
Stock Details
| Ticker Symbol | GRI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001824293 |
| ISIN Number | US3622AW2059 |
| Employer ID | 82-4369909 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. W. Marc Hertz Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Leanne M. Kelly | Chief Financial Officer and Corporate Secretary |
| Dr. Vipin Kumar Chaturvedi Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Albert Agro Ph.d. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 31, 2024 | 424B3 | Prospectus |
| May 31, 2024 | 424B3 | Prospectus |
| May 22, 2024 | 8-K | Current Report |
| May 21, 2024 | 424B3 | Prospectus |
| May 21, 2024 | 424B3 | Prospectus |
| May 20, 2024 | 8-K | Current Report |
| May 20, 2024 | 424B5 | Filing |
| May 16, 2024 | EFFECT | Notice of Effectiveness |
| May 14, 2024 | 424B3 | Prospectus |
| May 14, 2024 | 424B3 | Prospectus |